Assessing the tolerability and efficacy of first-line chemotherapy in elderly patients with metastatic HER2−ve breast cancer

BACKGROUND: In metastatic breast cancer (MBC), there is no consensus regarding the optimal regimen sequence and whether adults >65 years old (OA) are at increased risk from chemotherapy toxicity. Treatment decisions are often driven by the ability to tolerate treatment and maintain the quality of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Thomas, Dyke, Claire, Reed, Hannah, Hudson, Zoe, Robinson, Timothy, Di Nardo, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2019
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546255/
https://www.ncbi.nlm.nih.gov/pubmed/31281418
http://dx.doi.org/10.3332/ecancer.2019.921

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546255/
https://www.ncbi.nlm.nih.gov/pubmed/31281418
http://dx.doi.org/10.3332/ecancer.2019.921

Ejemplares similares